Moderna produced the most drugs in Korea in 2023

Driven by Spikevax production

MFDS publishes the 2023 Food and Drug Statistical Yearbook

Followed by 2nd place, Celltrion, 3rd place, Hanmi Pharmaceutical, 4th place, Chong Kun Dang

Moderna Korea has surpassed Celltrion and Hanmi Pharmaceutical and became the largest domestic pharmaceutical manufacturer in Korea in 2022.

 

The item that drove Moderna’s lead was the COVID-19 vaccine ‘Spikevax Inj,’, which accounted for 100% of Moderna Korea's total production value of KRW 1.275 trillion.

 

According to the '2023 Food and Drug Statistics Yearbook' recently published by the Ministry of Food and Drug Safety, the top 20 domestic pharmaceutical companies in 2022 in terms of the amount of drug production are Moderna Korea, No.

 

1, Celltrion, No.

 

2, Hanmi Pharmaceutical, No.

 

3, Chong Kun Dang, and No.

 

5, GC Biopharma.

 

Hanmi Pharmaceutical, which ranked first in 2018 and 2019, and Celltrion, which ranked first in 2020 and 2021, lost the top spot to Moderna Korea in 2022 due to the rise in supply of vaccines amid the spread of COVID-19.

 

Among the top 20 pharmaceutical companies in Korea, the companies with the highest manufacture amount exceeding KRW 1 trillion were Moderna Korea (KRW 1.275 trillion), Celltrion (KRW 1.226 trillion), Hanmi Pharmaceutical (KRW 1.018 trillion), and and Chong Kun Dang (KRW 1.594 trillion).

 

Two dosage forms of Spikevax were ranked first and second in terms of production of single products, followed by Celltrion's Remsima 100mg at KRW 184.9 billion, Handok's Plavix Tab 75mg at KRW 153.4 billion, and HK Inno.N's K-Cab 50mg at KRW 152.3 billion, Daewoong Pharmaceutical's 'Nabota' at KRW 127 billion, GC Biopharma’s 'GC Fluquadrivalent Prefilled Syringe Inj' at KRW 116.6 billion, and Chong Kun Dang’s ‘Chong Kun Dang’s Gliatorin Soft Cap' at KRW 107.9 billion, among drugs with an annual production amount that exceeds KRW 100 billion for a single item.

 

In particular, although reimbursement was reduced due to reimbursement revaluations for choline alfoscerate, the production of Chong Kun Dang’s Gliatorin Soft Capsule and Daewoong Bio's Gliatorin Soft Capsule (KRW 97.2 billion), representative choline alfoscerate products, still ranked 8th and 9th in Korea.

 

Among the top 20 global pharmaceutical companies, in 2022, AbbVie ($73 billion) ranked first, followed by Johnson & Johnson ($71 billion), then Novartis ($57 billion), Novo Nordisk ($50 billion), then Bristol-Myers Squibb ($49 billion).

 

The top 10 finished drug imports for 2022 were also listed, with Comirnaty Inj Veklury Intravenous Lyophilized Powder for Injection ranking No.

 

1, followed by Comirnaty 2 Injection 0.1mg/m, Spikevax Inj, Keytruda Inj, then Prolia Prefilled Syringe ranking the fifth.